Long-term retrospective analysis of gene therapy with Alipogene Tiparvovec and its effect on lipoprotein lipase deficiency-induced pancreatitis

Human Gene Therapy

Volumn 27, Issue 11, 2016, Pages 916-925

  Gaudet, Daniel ^a   Stroes, Erik S ^b   Méthot, Julie ^a   Brisson, Diane ^a   Tremblay, Karine ^a   Bernelot Moens, Sophie J ^b   Iotti, Giorgio ^c   Rastelletti, Irene ^c   Ardigo, Diego ^c   Corzo, Deyanira ^d   Meyer, Christian ^d   Andersen, Marc ^d   Ruszniewski, Philippe ^e   Deakin, Mark ^f   Bruno, Marco J ^g  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c CHIESI FARMACEUTICI S P A   (Italy)

^d UNIQURE   (Netherlands)

^e BEAUJON HOSPITAL   (France)

^f UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST   (United Kingdom)

^g ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

gene therapy, lipoprotein lipase deficiency, pancreatitis, chylomicronemia

Indexed keywords

ALIPOGENE TIPARVOVEC; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; TRIACYLGLYCEROL; LIPOPROTEIN LIPASE;

ACUTE ABDOMEN; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GENE THERAPY; HOSPITALIZATION; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTENSIVE CARE UNIT; MALE; PANCREATITIS; RETROSPECTIVE STUDY; ADMINISTRATION AND DOSAGE; COMPLICATION; DEFICIENCY; DEPENDOPARVOVIRUS; EUROPE; GENE VECTOR; GENETICS; MIDDLE AGED; TIME FACTOR; YOUNG ADULT;

ADULT; DEPENDOVIRUS; EUROPE; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; HYPERLIPOPROTEINEMIA TYPE I; LIPOPROTEIN LIPASE; MALE; MIDDLE AGED; PANCREATITIS; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84997294339     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2015.158     Document Type: Article

References (46)

1. Brunzell JD, Deeb SS. Familial lipoprotein lipase deficiency, Apo C-II deficiency and hepatic lipase deficiency. In. The Metabolic Basis of Inherited Disease. CR Scriver, AL Beaudet, WS Sly, et al., eds. McGraw-Hill, New York. 2001; pp. 2789-2816
2. Nierman MC, Rip J, Twisk J, et al. Gene therapy for genetic lipoprotein lipase deficiency: from promise to practice. Neth J Med 2005; 63: 14-19
3. Tremblay K, Méthot J, Brisson D, et al. Etiology and risk of lactescent plasma and severe hypertriglyceridemia. J Clin Lipidol 2011; 5: 37-44
4. Bruno MJ. Gene therapy coming of age-prevention of acute pancreatitis in lipoprotein lipase deficiency through alipogene tiparvovec. Eur Gastroenterol Hepatol Rev 2010; 6: 48-53
5. Banks PA, Freeman ML; Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines in acute pancreatitis. Am J Gastroenterol 2006; 101: 2379-2400
6. Chait A, Brunzell JD. Chylomicronemia syndrome. Adv Intern Med 1991; 37: 249-273
7. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996; 37: 693-707
8. Mahley RW, Ji Z-S. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein. Eur J Lipid Res 1999; 40: 1-16
9. Manno CS, Chew AJ, Hutchison S. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963-2972
10. McPhee SW, Janson CG, Li C, et al. Immune responses to AAV in a phase I study for Canavan disease. J Gene Med 2006; 8: 577-588
11. Flotte TR, Brantly ML, Spencer LT, et al. Phase I trial of intramuscular injection of a recombinant adeno-Associated virus a1-Antitrypsin (rAAV2-CBhAAT) gene vector to AAT-deficient adults. Hum Gene Ther 2004; 14: 93-128
12. Vincent-Lacaze N, Snyder RO, Gluzman R, et al. Structure of adeno-Associated virus vector DNA following transduction of the skeletal muscle. J Virol 1999; 73: 1949-1955
13. Rivera VM, Gao G-P, Grant RL, et al. Longterm pharmacologically regulated expression of erythropoietin in primates following AAVmediated gene transfer. Blood 2005; 105: 1424-1430
14. Monahan PE, Samulski RJ, Tazelaar J, et al. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther 1998; 5: 40-49
15. Sandalon Z, Bruckheimer EM, Lustig KH, et al. Long-Term suppression of experimental arthritis following intramuscular administration of a pseudotyped AAV2/1-TNFR: Fc vector. Mol Ther 2007; 15: 264-269
16. Rivière C, Danos O, Douar AM. Long-Term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther 2006; 13: 1300-1308
17. Rudich SM, Zhou S, Srivastava R, et al. Dose response to a single intramuscular injection of recombinant adeno-Associated virus - erythropoietin in monkeys. J Surg Res 2000; 90: 102-108
18. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease: a meta-Analysis. Circulation 1999: 99; 2901-2907
19. Rip J, Nierman MC, Ross CJ, et al. Lipoprotein lipase S447X: a naturally occurring gain-offunction mutation. Arterioscler Thromb Vasc Biol 2006; 26: 1236-1245
20. Gaudet D, Méthot J, Déry S, et al. Efficacy and long-Term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther 2013; 20: 361-369
21. Gaudet D, Brisson D, van Der Burgth M, et al. Safety and efficacy results from the long-Term follow-up of an open label study (CT-AMT-011-01) of alipogene tiparvovec (AAV1-LPLS447X) for lipoprotein lipase deficiency (LPLD). Abstract 759 presented at the International Symposium on Atherosclerosis 2015. www.pace-cme.org/bestanden/fd282635696976250695000-ISA-2015-Abstracts-751-1040-000328.pdf (last accessed August 8, 2016
22. Carpentier AC, Frisch F, Labbé SM, et al. Effect of alipogene tiparvovec (AAV1-LPLS447X) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab 2012; 97: 1635-1644
23. Twisk J, Frisch F, Ferreira V, et al. Long-Term transgene expression and biological effect following IM administration of AAV1-LPLS447X to LPL deficient patients. Mol Ther 1012; 20(Suppl 1): S23
24. Stroes ES, Nierman MC, Meulenberg JJ, et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 2008; 28: 2303-2304
25. European Medicines Agency. European public assessment report: Glybera (2012). www.ema .europa.eu (last accessed April 1, 2015
26. Banks PA, Bollen TL, Dervenis C, et al. Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013; 62: 102-111
27. Buchlis G, Podsakoff GM, Radu A, et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood 2012: 119: 3038-3041
28. Hegele R, Ginsberg H, Chapma JM, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014; 2: 655-666
29. Vlada AC, Schmit B, Perry A, et al. Failure to follow evidence-based best practice guidelines in the treatment of severe acute pancreatitis. HPB (Oxford) 2013; 15: 822-827
30. Lesser PB, Warshaw AL. Diagnosis of pancreatitis masked by hyperlipemia. Ann Intern Med 1975; 82: 795-798
31. Warshaw AL, Bellini CA, Lesser PB. Inhibition of serum and urine amylase activity in pancreatitis with hyperlipemia. Ann Surg 1975; 182: 72-75
32. Fortson MR, Freedman SN, Webster PD. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol 1995; 90: 2134-2139
33. Yadav D, Pitchumoni CS. Issues in hyperlipidemic pancreatitis. J Clin Gastroenterol 2003; 36: 54-62
34. Navarro S, Cubiella J, Feu F, et al. [Hypertriglyceridemic acute pancreatitis. Is its clinical course different from lithiasic acute pancreatitis?.] [article in Spanish]. Med Clin (Barc) 2004; 30: 567-570
35. Yoon YK, Ji JH, Mun BS. Hypertriglyceridemiainduced pancreatitis. Korean J Gastroenterol 2008; 51: 309-313
36. Senosiain Lalastra C, Tavío Hernaández E, Moreira Vicente V, et al. [Acute hypertrygliceridemic pancreatitis] [article in Spanish]. Gastroenterol Hepatol 2013; 36: 274-279
37. Brunzell JD, Schrott HG. The interaction of familial and secondary causes of hypertriglyceridemia: role in pancreatitis. Trans Assoc Am Physicians 1973; 86: 245-254
38. Cameron JL, Capuzzi DM, Zuidema GD, et al. Acute pancreatitis with hyperlipemia: the incidence of lipid abnormalities in acute pancreatitis. Ann Surg 1973: 177: 483-489
39. Howard JM, Ehrlich E, Spitzer JJ, et al. Hyperlipemia in patients with acute pancreatitis. Ann Surg 1964; 160: 210-214
40. Fallat RW, Vester JW, Glueck CJ, et al. Suppression of amylase activity by hypertriglyceridemia. JAMA 1973; 225: 1331-1334
41. Gaudet D, Méthot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr Opin Lipidol 2012; 23: 310-320
42. Gaudet D, Brisson D. Gene-based therapies in lipidology: current status and future challenges. Curr Opin Lipidol 2015; 26: 553-565
43. Salmon F, Grosios K, Petry H. Safety profile of recombinant adeno-Associated viral vectors: focus on alipogene tiparvovec (Glybera). Expert Rev 2014; 7: 53-65
44. Ferreira V, Petry H, Salmon F. Immune responses to AAV-vectors, the Glybera example from bench to bedside. Frontiers Immunol 2014; 5: 82
45. Saharia P, Margolis S, Zuidema GD, et al. Acute pancreatitis with hyperlipemia: studies with an isolated perfused canine pancreas. Surgery 1977; 82: 60-67
46. Nordstoga K, Christophersen B, Ytrehus B, et al. Pancreatitis associated with hyperlipoproteinaemia type I in mink (Mustela vison): earliest detectable changes occur in mitochondria of exocrine cells. J Comp Pathol 2006; 134: 320-328